STOCK TITAN

Moderna to Showcase Extensive Infectious Disease Research at ESCMID 2025

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

Moderna (NASDAQ:MRNA) has announced its participation in the ESCMID Global Congress in Vienna from April 11-15, 2025, where it will present extensive infectious disease research through twelve scientific presentations.

The presentations include research across multiple disease areas: COVID-19, influenza, respiratory syncytial virus (RSV), cytomegalovirus (CMV), norovirus, and mpox. The format includes three oral presentations, one e-poster presentation, and eight poster presentations.

Key highlights include presentations on: JN.1 and KP.2-encoding mRNA COVID-19 vaccines, six-month immunogenicity of mRNA-1345 RSV vaccine in adults aged ≥60 years, safety studies of mpox vaccine candidate mRNA-1769, and long-term safety data for cytomegalovirus mRNA-1647 vaccine.

Moderna (NASDAQ:MRNA) ha annunciato la sua partecipazione al Congresso Globale ESCMID a Vienna dal 11 al 15 aprile 2025, dove presenterà ampie ricerche sulle malattie infettive attraverso dodici presentazioni scientifiche.

Le presentazioni includono ricerche su più aree di malattia: COVID-19, influenza, virus respiratorio sinciziale (RSV), citomegalovirus (CMV), norovirus e mpox. Il formato prevede tre presentazioni orali, una presentazione e-poster e otto presentazioni poster.

I punti salienti includono presentazioni su: vaccini mRNA COVID-19 codificanti JN.1 e KP.2, immunogenicità a sei mesi del vaccino mRNA-1345 RSV negli adulti di età ≥60 anni, studi di sicurezza del candidato vaccino mpox mRNA-1769 e dati di sicurezza a lungo termine per il vaccino citomegalovirus mRNA-1647.

Moderna (NASDAQ:MRNA) ha anunciado su participación en el Congreso Global de ESCMID en Viena del 11 al 15 de abril de 2025, donde presentará amplias investigaciones sobre enfermedades infecciosas a través de doce presentaciones científicas.

Las presentaciones incluyen investigaciones en múltiples áreas de enfermedades: COVID-19, influenza, virus sincitial respiratorio (RSV), citomegalovirus (CMV), norovirus y mpox. El formato incluye tres presentaciones orales, una presentación de e-póster y ocho presentaciones de póster.

Los aspectos destacados incluyen presentaciones sobre: vacunas de ARNm COVID-19 que codifican JN.1 y KP.2, inmunogenicidad a seis meses de la vacuna de ARNm-1345 RSV en adultos de ≥60 años, estudios de seguridad del candidato a vacuna mpox mRNA-1769 y datos de seguridad a largo plazo para la vacuna de citomegalovirus mRNA-1647.

모더나 (NASDAQ:MRNA)는 2025년 4월 11일부터 15일까지 비엔나에서 열리는 ESCMID 글로벌 컨그레스에 참여한다고 발표했으며, 여기서 12개의 과학 발표를 통해 광범위한 감염병 연구를 발표할 예정입니다.

발표에는 여러 질병 영역에 대한 연구가 포함됩니다: COVID-19, 인플루엔자, 호흡기 세포융합바이러스(RSV), 거대세포바이러스(CMV), 노로바이러스 및 mpox. 형식에는 세 가지 구두 발표, 하나의 전자 포스터 발표 및 여덟 개의 포스터 발표가 포함됩니다.

주요 하이라이트에는 JN.1 및 KP.2를 암호화하는 mRNA COVID-19 백신, 60세 이상의 성인에서 mRNA-1345 RSV 백신의 6개월 면역원성, mpox 백신 후보 mRNA-1769의 안전성 연구 및 거대세포바이러스 mRNA-1647 백신에 대한 장기 안전성 데이터에 대한 발표가 포함됩니다.

Moderna (NASDAQ:MRNA) a annoncé sa participation au Congrès Mondial ESCMID à Vienne du 11 au 15 avril 2025, où elle présentera d'importantes recherches sur les maladies infectieuses à travers douze présentations scientifiques.

Les présentations incluent des recherches dans plusieurs domaines de maladies : COVID-19, grippe, virus respiratoire syncytial (VRS), cytomégalovirus (CMV), norovirus et mpox. Le format comprend trois présentations orales, une présentation de poster électronique et huit présentations de posters.

Les points forts incluent des présentations sur : les vaccins ARNm COVID-19 codant pour JN.1 et KP.2, l'immunogénicité à six mois du vaccin ARNm-1345 VRS chez les adultes de ≥60 ans, les études de sécurité du candidat vaccin mpox mRNA-1769 et les données de sécurité à long terme pour le vaccin cytomégalovirus mRNA-1647.

Moderna (NASDAQ:MRNA) hat seine Teilnahme am ESCMID Global Congress in Wien vom 11. bis 15. April 2025 angekündigt, wo es umfangreiche Forschungsarbeiten zu Infektionskrankheiten in zwölf wissenschaftlichen Präsentationen vorstellen wird.

Die Präsentationen umfassen Forschungen in mehreren Krankheitsbereichen: COVID-19, Influenza, respiratorisches Synzytialvirus (RSV), Zytomegalovirus (CMV), Norovirus und mpox. Das Format umfasst drei mündliche Präsentationen, eine E-Poster-Präsentation und acht Poster-Präsentationen.

Wichtige Highlights sind Präsentationen zu: JN.1- und KP.2-kodierenden mRNA COVID-19-Impfstoffen, der sechsmonatigen Immunogenität des mRNA-1345 RSV-Impfstoffs bei Erwachsenen ab 60 Jahren, Sicherheitsstudien des Impfstoffkandidaten mpox mRNA-1769 und langfristigen Sicherheitsdaten für den Zytomegalovirus mRNA-1647-Impfstoff.

Positive
  • Broad pipeline development across six infectious diseases
  • Multiple late-stage vaccine candidates in development
  • Continued progress in COVID-19 vaccine adaptations for new variants
Negative
  • None.

CAMBRIDGE, MA / ACCESS Newswire / April 7, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present research across multiple infectious disease areas, including COVID-19, influenza, respiratory syncytial virus (RSV), cytomegalovirus (CMV), norovirus, and mpox, at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Vienna, Austria, from April 11-15, 2025.

Moderna will present twelve scientific presentations at the ESCMID 2025 Global Congress, including three oral presentations, one e-poster presentation, and eight poster presentations, highlighting the breadth of its research in respiratory and emerging infectious diseases.

COVID-19

  • Immunogenicity of JN.1- and KP.2-encoding mRNA COVID-19 vaccines against JN.1 SARS-CoV-2 sublineages in adult participants - Oral Presentation
    Presenter: Frances Priddy
    Session: Advances in vaccine effectiveness for viral respiratory infections
    Date: April 12 | Time & Location: 11:00 (Hall 9)

  • Relative vaccine efficacy of a SARS-CoV-2 spike receptor-binding and N-terminal domain COVID-19 vaccine versus mRNA-1273: subgroup analyses - Oral Presentation
    Presenter: Spyros Chalkias
    Session: Vaccines and prophylaxis against respiratory viral infections
    Date: April 13 | Time & Location: 11:00 (Hall 9)

  • Clinical evaluation of a SARS-CoV-2 spike receptor-binding and N-terminal domain COVID-19 vaccine - Poster Presentation
    Presenter: Spyros Chalkias
    Session: COVID-19
    Date: April 12 | Time & Location: 12:00 (Poster Hall)

  • Immunogenicity and safety of a SARS-CoV-2 N-terminal domain and receptor-binding domain monovalent XBB.1.5 vaccine in Japanese participants aged ≥12 years - Poster Presentation
    Presenter: Christina Grassi
    Session: COVID-19
    Date: April 12 | Time & Location: 12:00 (Poster Hall)

RSV

  • Six-month Immunogenicity of mRNA-1345 RSV Vaccine in Adults Aged ≥60 Years - E-Poster Presentation
    Presenter: Mihir Desai
    Session: On the frontiers of vaccine-driven prevention
    Date: April 12 | Time & Location: 08:30 (Arena 1)

  • Safety and immunogenicity of mRNA-1345 revaccination at 24 months in adults ≥60 years - Poster Presentation
    Presenter: Mihir Desai
    Session: Clinical Trials
    Date: April 15 | Time & Location: 12:00 (Poster Hall)

  • Burden of chronic medical conditions that are risk factors for severe RSV among adults aged 18-59 years in the United States - Poster Presentation
    Presenter: Clarisse Demont
    Session: Influenza and respiratory viruses
    Date: April 12 | Time & Location: 12:00 (Poster Hall)

  • Association of virology swab positivity in adults aged ≥40 years with Computerized Medical Record Reported Acute Respiratory Infection (ARI) Subgroups: Observational Study of ARI (ObservatARI) - Poster Presentation
    Presenter: Simon De Lusignan
    Session: Influenza and respiratory viruses
    Date: April 12 | Time & Location: 12:00 (Poster Hall)

Mpox

  • Safety and immunogenicity of mRNA mpox vaccine candidate mRNA-1769: Interim analysis results from a Phase 1/2 Trial - Oral Presentation
    Presenter: Hiwot Hiruy
    Session: Novel vaccines in clinical development
    Date: April 14 | Time & Location: 17:30 (Hall 3)

Cytomegalovirus

  • Long-term safety and immunogenicity of cytomegalovirus mRNA-1647 vaccine in healthy adults: 36-month results from a phase 2 extension trial - Poster Presentation
    Presenter: Ben Lorenz
    Session: Clinical Trials
    Date: April 15 | Time & Location: 12:00 (Poster Hall)

Influenza

  • Six-month persistence and safety of mRNA-based influenza or multicomponent influenza/COVID-19 vaccines versus licensed comparators in adults aged ≥18 years - Poster Presentation
    Presenter: Mieke Soens
    Session: Influenza and respiratory viruses
    Date: April 12 | Time & Location: 12:00 (Poster Hall)

Norovirus

  • Incidence and severity of sporadic, medically attended norovirus infection in the United States, 2023-2024 - Poster Presentation
    Presenter: Mark A. Schmidt
    Session: Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology
    Date: April 12 | Time & Location: 12:00 (Poster Hall)

About Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.

Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the potential for Moderna's vaccine candidates to alleviate disease outcomes. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.

Moderna Contacts

Media:
Luke Mircea-Willats
Senior Director, International Communications
Luke.Mirceawillats@modernatx.com

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna Inc.



View the original press release on ACCESS Newswire

FAQ

What research will Moderna present at ESCMID 2025?

Moderna will present 12 scientific presentations covering COVID-19, influenza, RSV, CMV, norovirus, and mpox research at ESCMID 2025 in Vienna from April 11-15.

What are the key COVID-19 vaccine studies MRNA will present?

MRNA will present studies on JN.1 and KP.2-encoding vaccines, including immunogenicity data and relative vaccine efficacy of SARS-CoV-2 spike receptor-binding and N-terminal domain vaccines.

What RSV vaccine data will MRNA showcase at ESCMID 2025?

MRNA will present six-month immunogenicity data for mRNA-1345 RSV vaccine in adults ≥60 years and 24-month revaccination safety data.

What are the latest developments in MRNA's mpox vaccine research?

MRNA will present interim analysis results from a Phase 1/2 trial on the safety and immunogenicity of their mpox vaccine candidate mRNA-1769.
Moderna

NASDAQ:MRNA

MRNA Rankings

MRNA Latest News

MRNA Stock Data

9.75B
358.52M
7.27%
72.77%
11.68%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
CAMBRIDGE